A Single Arm Phase II Study to Investigate the Use of Lenalidomide in the Treatment of Patients With Early Stage CLL Associated With Poor Prognostic Factors.

Trial Profile

A Single Arm Phase II Study to Investigate the Use of Lenalidomide in the Treatment of Patients With Early Stage CLL Associated With Poor Prognostic Factors.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESPeCT
  • Most Recent Events

    • 02 Apr 2012 Actual end date (1 Apr 2012) added as reported by ISRCTN: Current Controlled Trials record.
    • 02 Apr 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 04 Dec 2011 United Kingdom Clinical Research Network reports accrual to date changed from 20% to 25%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top